Rheumatologic diseases and posterior reversible encephalopathy syndrome: Two case reports and review of the literature

Rheumatology International

Volumn 32, Issue 12, 2012, Pages 3707-3713

  Dhillon, Anmol ^a   Velazquez, Celso ^a   Siva, Chokkalingam ^a  

^a University of Missouri   (United States)

Author keywords

Immunosuppressive medications; PRES; Rheumatologic diseases

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; LABETALOL; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENYTOIN; PREDNISONE; TACROLIMUS; VALPROIC ACID; VINBLASTINE;

ADOLESCENT; ADULT; BLOOD PRESSURE; CEREBRAL BLINDNESS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LOW DRUG DOSE; MENTAL HEALTH; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; POLYARTERITIS NODOSA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCHOOL CHILD; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VOMITING; WEGENER GRANULOMATOSIS;

ADULT; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; SCLERODERMA, SYSTEMIC;

EID: 84872265626     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2476-3     Document Type: Review

References (31)

1. Mukherjee P (2001) Reversible posterior leukoencephalopathy syndrome: Evaluation with diffusion-tensor MR imaging1. Radiol 219:756-765
2. Hinchey J, Chaves C, Appignani B et al (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334(8): 494-500
3. Feske SK (2011) Posterior reversible encephalopathy syndrome: A review. Semin Neurol 31(2):202-215
4. Kahn JS, Romano S, Andiman WA (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334(26):1745 author reply 1746-5
5. Schwartz R, Bravo S, Klufas R et al (1995) Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. Am J Roentgenol 165(3):627
6. Kastrup O, Christoph Diener H (2008) TNF-antagonist etanercept induced posterior leukoencephalopathy syndrome. J Neurol 255:452-453
7. Gijtenbeek JM, Van den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: A review. J Neurol 246:339-346
8. Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 2: Controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol 29(6):1043-1049
9. Gottrand F, Largilliere C, Farriaux JP (1991) Cyclosporine neurotoxicity. N Engl J Med 324(24):1744-1745
10. Preston GA, Yang JJ, Xiao H, Falk RJ (2002) Understanding the pathogenesis of ANCA: Where are we today? Clevel Clin J Med 69(2):SII51-SII54
11. Poon WL, Mok CC (2005) Reversible posterior leucoencephalopathy in scleroderma. Annu Rheum Dis 64(12):1803-1804
12. Lopez-Garcia F, Amoros-Martinez F, Sempere AP (2004) A reversible posterior leukoencephalopathy syndrome. Rev Neurol 38(3):261-266
13. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA (2010) Posterior reversible encephalopathy syndrome: Associated clinical and radiologic findings. Mayo Clin Proc 85(5):427-432
14. Balow J (1985) Renal vasculitis. Kidney Int 26(6):954-964
15. Stanzani L, Fusi L, Gomitoni A, Roncoroni M, Villa P, Grampa G (2008) A case of posterior reversible encephalopathy during polyarteritis nodosa vasculitis. Neurol Sci 29(3):163-167
16. Ohta T, Sakano T, Shiotsu M et al (2004) Reversible posterior leukoencephalopathy in a patient with Wegener granulomatosis. Pediatr Nephrol 19(4):442-444
17. Del Castillo-Pinol N, Robustillo-Villarino M, Narvaez JA, Narvaez J (2010) Reversible posterior leukoencephalopathy in diffuse scleroderma. Clin Exp Rheumatol 28(2 Suppl 58):63-64
18. Renard D, Westhovens R, Vandenbussche E, Vandenberghe R (2004) Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 251:226-228
19. Marcon G, Giovagnoli AR, Mangiapane P, Erbetta A, Tagliavini F, Girotti F (2009) Regression of chronic posterior leukoencephalopathy after stop of methotrexate treatment. Neurol Sci 30:375-378
20. Raghavendra S, Nair MD, Chemmanam T, Krishnamoorthy T, Radhakrishnan VV, Kuruvilla A (2007) Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate. Eur J Neurol 14:309-314
21. Shin KC, Choi HJ, Bae YD, Lee JC, Lee EB, Song YW (2005) Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine. J Clin Rheumatol 11(3):164-166
22. Filley CM, Kleinschmidt-DeMasters BK (2001) Toxic leukoencephalopathy. N Engl J Med 345:425-432
23. Giuseppe S, Bifulco E, De Robertis F, Piazza O, Striano P, Tortora F, Striano S, Tufano R (2006) Posterior reversible encephalopathy syndrome. Intensive Care Med 33(2):230-236
24. Ay H, Buonanno F, Schaefer P, Le D (1988) Posterior leukoencephalopathy without severe hypertension. Neurology 51(5): 1369-1376
25. Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM (2004) Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 77(1):72-76
26. Seze JD, Mastain B, Stojkovic T et al (2000) Unusual MR findings of the brain stem in arterial hypertension. Am J Neuroradiol 21(2):391
27. Min L, Zwerling J, Ocava LC, Chen IHA, Putterman C (2006) Reversible posterior leukoencephalopathy in connective tissue diseases. Semin Arthritis Rheum 35(6):388-395
28. Vaughan CJ, Delanty N (2000) Hypertensive emergencies. Lancet 356(9227):411-417
29. Neutel JM, Smith DH, Wallin D et al (1994) A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am J Hypertens 7(7 Pt 1):623-628
30. Bakshi R, Bates VE, Mechtler LL, Kinkel PR, Kinkel WR (1998) Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: Magnetic resonance imaging findings. Epilepsia 39(3):295-299
31. Eberly AL, Anderson GD, Bubalo JS, McCune JS (2008) Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 28(12):1502-1510